• Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.

    March 23, 2021

    PHILADELPHIA and NEW YORK, March 23, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor" or the "Company"), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular and central nervous system (CNS) diseases resulting from BAG3 gene dysfunction, and Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company or SPAC, sponsored by affiliates of Chardan Capital Markets ("Chardan"), announced today they have entered into a definitive business combination agreement. Upon closing of the transaction, CHAQ will be re

    Read More
  • Basking Biosciences, Inc. Completes $5.4M Seed Financing

    December 7, 2020

    December 07, 2020 08:30 AM Eastern Standard Time COLUMBUS, Ohio--(BUSINESS WIRE)--Basking Biosciences, Inc. (Basking), a privately-held biopharmaceutical company developing a next generation treatment for acute ischemic stroke (AIS) announced an initial closing of a $5.4M Seed Series financing. The investor syndicate includes Rev1 Ventures, Broadview Ventures and Viva BioInnovator. Concurrent with the financing, Ryan Helon of Rev1, Thomas Needham of Broadview and Dr. Dan Meyers have joined Basking’s Board of Directors. Read full press release here.

    Read More
  • Vectorious’ in-heart microcomputer wins FDA breakthrough nod

    November 30, 2020

    November 30, 2020. Vectorious Medical Technologies today announced that the FDA has granted breakthrough device designation for the company’s left atrial pressure (LAP) monitoring device. The V-LAP system is the first digital, wireless, battery-free device that can communicate from deep within the body using high-resolution waveform morphology, according to the Tel Aviv-based startup. Because the pressure of the heart’s left atrium is the earliest and most accurate real-time indication of heart failure exacerbation, company officials believe the feedback provided by the V-LAP will enabl

    Read More
  • FineHeart Achieves Milestone for its Miniaturized Heart Pump Technology with Successful Completion of 30-Day Preclinical Study

    October 20, 2020

    Bordeaux, France - October 20, 2020. – FineHeart, SA, a preclinical-stage medical device company developing an Implantable Cardiac Output Management System (ICOMS) to address the unmet need of patients suffering from severe heart failure, today announced the successful completion of a 30-day preclinical study. The 30-day trial confirms the device’s ability to provide hemodynamic performance with pulsed and continuous increased cardiac output of up to 6L/min; it demonstrated a low risk of hemolysis and thrombosis. Read full press release here.

    Read More
  • FineHeart: An LVAD Works in Synchrony with the Heart

    July 22, 2020

    Founded by electrophysiologists, FineHeart has developed an LVAD that is like no other. It resides inside the left ventricle of the heart where it times the blood flow it generates with the opening and closing of the aortic valve, thus achieving a physiologic and pulsatile flow. Read more here.

    Read More
  • ZZ Biotech Announces FDA Fast Track Designation for Stroke Program

    June 12, 2020

    HOUSTON, USA, June 12, 2020 / B3C newswire / -- ZZ Biotech today announced that the US Food and Drug Administration (FDA) has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischemic stroke as a Fast Track development program. Read full press release here.

    Read More
  • Kantum Pharma Highlights New Research Demonstrating Beneficial Effects of P2Y14 Antagonist in Acute Kidney Injury

    May 27, 2020

    CAMBRIDGE, Mass., May 27, 2020 /PRNewswire/ -- Kantum Pharma Inc. (Kantum), a biopharmaceutical company focused on developing therapies for the prevention and treatment of damaging inflammation triggered by the innate immune system, announced today the publication of new research demonstrating the therapeutic potential of the Company's lead program for preventing and treating acute kidney injury (AKI). The paper, which describes the groundbreaking research on the uridine diphosphate (UDP)-glucose/P2Y14 receptor signaling pathway in the kidney led by Kantum's scientific founder Dr. Sylvie Breto

    Read More
  • FineHeart Completes First Successful Chronic In-Vivo Study of its ICOMS Device Intended for the Treatment of Severe Heart Failure

    May 5, 2020

    Bordeaux, May 5, 2020 – FineHeart, a French medical device company, today announced the success of a seven-day preclinical study to evaluate its Implantable Cardiac Output Management System (ICOMS), the first fully Intra-Ventricular Flow Accelerator synchronized to the native heartbeat to restore natural heart pumping capacity. Read full press release here.

    Read More
  • Acesion Pharma Strengthens Clinical Team with Key Appointments

    May 7, 2020

    Copenhagen, 5 May 2020. Acesion Pharma, a Danish pharmaceutical company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, today announced that it has recruited Anders Gaarsdal Holst as its Chief Medical Officer (CMO) to succeed Nils Edvardsson, who will continue to support the company as Medical Adviser. In addition, Acesion Pharma has further strengthened the clinical team by recruiting Birgitte Vestbjerg as Director Clinical Operations. Read full press release here.

    Read More
  • AtaCor Medical Secures $25M Financing to Continue Extracardiac Pacing Development

    April 28, 2020

    April 28, 2020 SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that is has completed a $25M Series B financing. The financing syndicate, led by a corporate partner, includes existing investors Broadview Ventures and aMoon Fund as well as new investors Hatteras Venture Partners, Catalyst Health Ventures (CHV) and Longview Ven-tures, a Broadview affiliate. The investment supports efforts to reach US and EU regula-tory clearances for AtaCor’s novel extracardiac temporary pacing system as well as development efforts for additional extracardiac therapies. Re

    Read More